MedTrace Logo

An Extension to Study MD7108240

NCT00733304 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-12-05

Study results available
· View outcomes & findings →

Summary

This is a two month study to allow continued treatment with pazopanib eye drops. Study may be extended to 5 months.

Conditions

  • Macular Degeneration

Interventions

DRUG

Pazopanib

5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-25
Primary Completion
2009-09-09
Completion
2009-09-09

Countries

  • United States
  • Australia
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733304 on ClinicalTrials.gov